Known targets — ChEMBL curated mechanism
CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8
The experimentally established mechanism targets of Gabapentin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA2D1 known ✓ | P54289 | 1/20 | 0.96 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.96 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.96 |
| ▸ | USP2 | O75604 | 1/20 | 0.96 |
| ▸ | LMNA | P02545 | 1/20 | 0.96 |
| ▸ | TSHR | P16473 | 1/20 | 0.96 |
| ▸ | BLM | P54132 | 1/20 | 0.96 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.96 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Gabapentin SCHEMBL6689206 | 1.00 | CYP1A2 (0.96) | CYP1A2ALDH1A1USP2LMNATSHR | |
| Hydrochloric Acid SCHEMBL7340062 | 1.00 | CYP1A2 (0.96) | CYP1A2ALDH1A1USP2LMNATSHR | |
| Gabapentin SCHEMBL3238880 | 0.98 | CYP1A2 (0.92) | CYP1A2ALDH1A1USP2LMNATSHR | |
| Gabapentin SCHEMBL28968673 | 0.98 | CYP1A2 (0.92) | CYP1A2ALDH1A1USP2LMNATSHR | |
| Gabapentin SCHEMBL3117115 | 0.98 | CYP1A2 (0.92) | CYP1A2ALDH1A1USP2LMNATSHR | |
| Gababutin SCHEMBL2858085 | 0.98 | ALDH1A1 (0.91) | CYP1A2ALDH1A1USP2LMNATSHR | |
| Gabapentin SCHEMBL4030100 | 0.98 | CYP1A2 (1.00) | CYP1A2ALDH1A1USP2LMNATSHR | |
| Gabapentin SCHEMBL8343 | 0.98 | CYP1A2 (1.00) | CYP1A2ALDH1A1USP2LMNATSHR | |
| SCHEMBL6544499 | 0.98 | CYP1A2 (1.00) | CYP1A2ALDH1A1USP2LMNATSHR | |
| Gabapentin SCHEMBL179836 | 0.98 | CYP1A2 (1.00) | CYP1A2ALDH1A1USP2LMNATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 652 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260069579-A1 | COMPOSITIONS AND METHODS FOR PAIN RELIEF AND NUMBING | RELIEVE THERAPEUTICS PTE. LTD. (SG) | 2026-03-12 | — | — | US | claimed |
| US-20250163379-A1 | METHOD FOR DIFFERENTIATING HEMATOPOIETIC STEM/PROGENITOR CELLS INTO NK CELLS | HEMACELL BIOTECHNOLOGY INC. (CN) | 2025-05-22 | — | — | US | claimed |
| CN-118786209-A | Method for differentiating hematopoietic stem/progenitor cells into NK cells | 苏州血霁生物科技有限公司 | 2024-10-15 | — | — | CN | claimed |
| CN-116675615-B | Synthesis method of high-purity gabapentin | 浙江竹子制药有限公司 | 2024-07-26 | — | — | CN | claimed |
| CN-116693410-B | Preparation method of gabapentin with controllable particle size | 浙江竹子制药有限公司 | 2024-06-07 | — | — | CN | claimed |
| CN-116693410-A | Preparation method of gabapentin with controllable particle size | 浙江竹子制药有限公司 | 2023-09-05 | — | — | CN | claimed |
| CN-116675615-A | Synthesis method of high-purity gabapentin | 浙江竹子制药有限公司 | 2023-09-01 | — | — | CN | claimed |
| CN-113398995-B | Synthesis and application of photocatalyst 1- (aminomethyl) cyclohexyl acetic acid salicylaldehyde Schiff base-copper (II) microcrystal | 西南林业大学 | 2023-08-15 | — | — | CN | claimed |
| US-20220160689-A1 | COMPOSITIONS AND METHODS FOR PAIN RELIEF AND NUMBING | Ziropa, Inc. (US) | 2022-05-26 | — | — | US | claimed |
| CN-113398995-A | Synthesis and application of novel photocatalyst 1- (aminomethyl) cyclohexyl acetic acid shrinkage salicylaldehyde Schiff base-copper (II) microcrystal | 西南林业大学 | 2021-09-17 | — | — | CN | claimed |
| US-6518456-B1 | Process for the production and purification of gabapentin, i.e. 1-(aminomethyl)cyclohexyl-acetic acid, which comprises hydrolysis of 2-aza-spiro(4.5)decan-3-one with HCl, treatment of the resulting product and filtration with | PROCOS S.P.A. (IT) | 2003-02-11 | — | — | US | claimed |
| WO-2002044123-A1 | A PROCESS FOR THE PREPARATION OF 1-(AMINOMETHYL) CYCLOHEXANEACETIC ACID | ERREGIERRE S.P.A. (IT) | 2002-06-06 | — | — | WO | claimed |
| WO-2002034709-A1 | PROCESS FOR THE PREPARATION OF GABAPENTIN | ZAMBON GROUP S.P.A. (IT) | 2002-05-02 | — | — | WO | claimed |
| EP-1174418-A1 | PROCESS FOR THE PREPARATION OF PHARMACEUTICAL GRADE GABAPENTIN | Medichem S.A. (ES) | 2002-01-23 | — | — | EP | claimed |
| EP-1165489-A1 | A PROCESS FOR THE PREPARATION OF GABAPENTIN | Bioindustria Laboratorio Italiano Medicinali S.p.a. (IT) | 2002-01-02 | — | — | EP | claimed |
| US-6255526-B1 | REACTING SOLUTION OF GABAPENTIN HYDROCHLORIDE WITH ADDITIONAL AMINE IN A FIRST SOLVENT TO PRODUCE POLYMORPHIC PRECIPITATE FORM, THEN RECOVERING CONVERTED FORM FROM METHANOL SLURRY AND/OR CRYSTALLIZATION; TREATMENT OF CEREBRAL DISEASES | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2001-07-03 | — | — | US | claimed |
| WO-2000058268-A1 | A PROCESS FOR THE PREPARATION OF GABAPENTIN | BIOINDUSTRIA LABORATORIO ITALIANO MEDICINALI S.P.A. (IT) | 2000-10-05 | — | — | WO | claimed |
| EP-0950044-A1 | PREPARATION OF GABAPENTIN | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 1999-10-20 | — | — | EP | claimed |
| WO-1998028255-A1 | PREPARATION OF GABAPENTIN | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 1998-07-02 | — | — | WO | claimed |
| US-5091567-A | Reacting cyclohexanone with phosphonoacetic acid ester, condensing with nitromethane, reducing, hydrolyzing | GODECKE AKTIENGESELLSCHAFT (DE) | 1992-02-25 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260069579-A1 | COMPOSITIONS AND METHODS FOR PAIN RELIEF AND NUMBING | GABRE, GJB2, PMP22 | CACNA2D1 225/4885CYP1A2 3014/4885ALDH1A1 1220/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.